A Comparative Population-Based Analysis of Sinonasal Diffuse Large B-Cell and Extranodal NK/T-Cell Lymphomas

作者：Dubal Pariket M; Dutta Rahul; Vazquez Alejandro; Patel Tapan D; Baredes Soly; Eloy Jean Anderson^*

来源：Laryngoscope, 2015, 125(5): 1077-1083.

DOI：10.1002/lary.25111

• DLBCL
• diffuse large B-cell lymphoma
• ENKTL
• extranodal natural killer/T-cell lymphoma
• sinonasal malignancy
• SEER
• demographic
• incidence
• disease-specific survival
• sinonasal lymphoma

Objective/HypothesisDiffuse large B-cell lymphoma (DLBCL) and extranodal natural killer/T-cell lymphoma (ENKTL) are aggressive tumors. ENTKL is very rare in the United States and often affects the nasal cavity and paranasal sinuses; DLBCL, although more common, rarely occurs in these locations. Our study aims to compare incidence and survival of these lymphomas in the sinonasal cavity.
Study DesignRetrospective analysis of the United States National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) registry.
MethodsThe SEER database was searched for patients diagnosed with sinonasal ENKTL and DLBCL between 1973 and 2011. Data analyzed included patient demographics, incidence, treatment modality, and survival.
ResultsThree hundred and twenty-eight sinonasal ENKTL (SN-ENKTL) cases and 1,054 sinonasal DLBCL (SN-DLBCL) cases were identified. The mean ages at diagnosis for SN-ENKTL and SN-DLBCL were 51.7 and 67.8 years, respectively (P=0.0001). Overall 1-, 5-, and 10-year disease-specific survival (DSS) rates for SN-DLBCL were 85.5%, 63.5%, and 44.0%, compared to 66.4%, 30.9%, and 9.2% for SN-ENKTL, respectively (P<0.0001). For patients matched for stage, age, and treatment modality, the 1-, 5-, and 10-year DSS for the SN-DLBCL group was 94.4%, 72.8%, and 46.8%, respectively, whereas the respective survival rates for the SN-ENKTL group were 77.6%, 38.4%, and 13.9%, respectively (P<0.0001 at each time interval).
ConclusionsTo our knowledge, this study represents the only population-based comparison between SN-DLBCL and SN-ENKTL. SN-DLBCL has a better prognosis regardless of gender, stage, treatment modality, and age.
Level of Evidence2b. Laryngoscope, 125:1077-1083, 2015

• 出版日期2015-5